Nuevas terapias dirigidas para el tratamiento del cáncer

Autor/innen

  • José Manuel Jiménez Heras
  • Laura Lindo Yugueros
  • Laura Maeso Alonso
  • Daniel Martínez Manuel
  • Lorena Mata Gómez
  • Ana Pariente Delgado
  • Cayetano Pleguezuelos Manzano
  • Israel Prada García
  • Pablo Prieto Fuentes
  • Patricia Primo Arias
  • Ignacio Prusen Mota
  • Gabriel Ramírez Nieto
  • Daniel Roca Lema
  • Sonia Sánchez Bezanilla
  • Natalia Sanz Gómez
  • Eider Valle Encinas
  • Roberto Vázquez Fernández
  • Cristina Vega Carbajal
  • Paloma Vicario Sánchez
  • Lucía Villamañán de Santiago
  • Irene Villar Rúa
  • María C. Marín

DOI:

https://doi.org/10.18002/ambioc.v0i9.5564

Abstract

El cáncer es el término que se utiliza para englobar un conjunto de enfermedades que se caracterizan por el crecimiento descontrolado de célular alteradas molicularmente por mutaciones o modificaciones epigenéticas. En la presente revisión describimos algunas terapias dirigidas que se están utilizando actualmente en clínica.

Downloads

Keine Nutzungsdaten vorhanden.

Literaturhinweise

Artigas, C.G., Melo, A. et al. 2003. Transcriptos de fusión del gen bcr-abl en pacientes con leucemia mieloide crónica. International Journal of Morphology. 21:205209.

Bumbea, H., Vladareanu, A.M. et al. 2010. Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors the first molecular targeted treatment. Journal of Medicine and Life. 3:162166.

Cervantes F. 2008. Leucemia mieloide crónica. Medicina Clínica. 131:658659.

Cohen, M.H., Moses, M.L. et al. 2002. Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status. Oncologist. 7:390392.

Daley, G.Q. 2003. Gleevec resistance: lessons for targetdirected drug development. Cell Cycle. 2:190191.

Fakler, M., Loeder, S., et al. 2009. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl2mediated resistance. Blood. 113:17101722.

Gaestel, M., Mengel, A. et al. 2007. Protein kinases as small molecule inhibitor targets in inflammation. Current Medicinal Chemistry. 14:22142234.

Guertin D.A. y Sabatini D.M. 2005. An expanding role for mTOR in cancer. Trends in Molecular Medicine. 11:353361.

Guertin, D.A. y Sabatini, D.M. 2007. Defining the Role of mTOR in Cancer. Cancer Cell. 12:922.

Hail, N., Carter, B.Z, Konopleva, M. y Andreeff, M. 2006. Apoptosis effector mechanisms: A requiem performed in different keys. Apoptosis. 11:889-904.

Lowe, S.W. y Lin, A.W. 1999. Apoptosis in cancer. Carcinogenesis. 21: 485495.

Nagar, B. 2007. C-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI571). Journal Nutrition. 137:1518S1523S; discussion 1548S.

Neviani, P., Santhanam, R. et al. 2007. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosomepositive acute lymphocytic leukemia. The Journal of Clinical Investigation. 117:24082421.

Olayioye, M.A. 2001. Intracellular signaling pathways of ErbB2/HER2 and familiy members. Breast Cancer Research. 3:385389.

O'Reilly, T., Vaxelaire, J., Muller, M. et al. 2002. In vivo activity of RAD 001, an orally active rapamycin derivative, in experimental tumor models. Proceedings of the American Association for Cancer Research. 43:Abstr 359.

Pukac, L., Kanakara, P., et al. 2005. HGSETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. British Journal of Cancer. 92:14301441.

Schmitt, C.A. y Lowe, S.W. 1999. Apoptosis and therapy. Journal of Pathology. 187:127137.

Schuler, W., Sedrani, R., Cottens, S. et al. 1997. SDZRAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 64:3642.

Veröffentlicht

2013-07-24

Zitationsvorschlag

Jiménez Heras, J. M., Lindo Yugueros, L., Maeso Alonso, L., Martínez Manuel, D., Mata Gómez, L., Pariente Delgado, A., Pleguezuelos Manzano, C., Prada García, I., Prieto Fuentes, P., Primo Arias, P., Prusen Mota, I., Ramírez Nieto, G., Roca Lema, D., Sánchez Bezanilla, S., Sanz Gómez, N., Valle Encinas, E., Vázquez Fernández, R., Vega Carbajal, C., Vicario Sánchez, P., Villamañán de Santiago, L., Villar Rúa, I., & Marín, M. C. (2013). Nuevas terapias dirigidas para el tratamiento del cáncer. Ambiociencias, (9), 15–29. https://doi.org/10.18002/ambioc.v0i9.5564

Ausgabe

Rubrik

Poniendo en claro

Am häufigsten gelesenen Artikel dieser/dieses Autor/in